Science

hubble-back-in-service-after-gyro-scare—nasa-still-studying-reboost-options

Hubble back in service after gyro scare—NASA still studying reboost options

The Hubble Space Telescope viewed from Space Shuttle Atlantis during a servicing mission in 2009.

Enlarge / The Hubble Space Telescope viewed from Space Shuttle Atlantis during a servicing mission in 2009.

NASA

The Hubble Space Telescope resumed science observations on Friday after ground teams spent most of the last three weeks assessing the performance of a finicky gyroscope, NASA said.

The troublesome gyroscope is a critical part of the observatory’s pointing system. Hubble’s gyros measure how fast the spacecraft is turning, helping the telescope aim its aperture toward distant cosmic wonders.

Hubble still provides valuable scientific data for astronomers nearly 34 years since its launch aboard NASA’s Space Shuttle Discovery in 1990. Five more shuttle servicing missions repaired Hubble, upgraded its science instruments, and replaced hardware degraded from long-term use in space. Among other tasks, astronauts on the last of the shuttle repair flights in 2009 installed six new gyroscopes on Hubble.

Moving parts sometimes break

The gyros have long been one of the parts of Hubble that require the most upkeep. A wheel inside each gyro spins at a constant rate of 19,200 revolutions per minute, and the wheel is, in turn, sealed inside a cylinder suspended in a thick fluid, according to NASA. Electronics within each gyro detect very small movements of the axis of the wheel, which supply Hubble’s central computer with information about the spacecraft’s turn rate. Hair-thin wires route signals from the gyroscopes, and these wires can degrade over time.

Three of the six gyros installed on Hubble in 2009 have failed, and three others remain operational. The three still-functioning gyros are based on a newer design for longer life, but one of these units has shown signs of wear in the last few months. This gyroscope, designated Gyro 3, has always exhibited “consistent noisy behavior,” said Pat Crouse, Hubble project manager at NASA’s Goddard Space Flight Center.

Hubble typically needs three gyros to operate normally, so ground controllers shut down Gyro 3 for roughly seven years until Hubble needed it in 2018, when another gyroscope failed, leaving only three of the devices still working.

“Back in August, we saw issues,” Crouse told Ars this week. “It would sort of sporadically output some rate information that was not consistent with the observed spacecraft body rates, but it was short-lived, and we were characterizing what that performance was like and how much we could tolerate.”

The gyro’s performance worsened in November when it fed Hubble’s control system erroneous data. The gyroscope sensed that the spacecraft was changing its orientation when it really wasn’t moving. “That, then, contributed to an error in attitude that was kind of causing a little bit of drift,” Crouse said.

Automated software on Hubble detected the errors and put the spacecraft into “safe mode” two times last month. Hubble quickly resumed science observations each time but then went into safe mode again on November 23. Hubble managers took some extra time to gather data on the gyro’s health. Engineers commanded Hubble to move back and forth, and the suspect gyro consistently seemed to work well.

Hubble back in service after gyro scare—NASA still studying reboost options Read More »

fda-approves-first-crispr-therapy—here’s-how-it-works-against-sickle-cell

FDA approves first CRISPR therapy—here’s how it works against sickle cell

historic —

The landmark treatment turns on another blood protein that prevents sickling.

This digitally colorized scanning electron micrograph (SEM) revealed some of the comparative ultrastructural morphology between normal red blood cells (RBCs), and a sickle cell RBC (left) found in a blood specimen of an 18-year-old female patient with sickle cell anemia.

Enlarge / This digitally colorized scanning electron micrograph (SEM) revealed some of the comparative ultrastructural morphology between normal red blood cells (RBCs), and a sickle cell RBC (left) found in a blood specimen of an 18-year-old female patient with sickle cell anemia.

The Food and Drug Administration on Friday approved two gene therapies to treat sickle cell disease, one of the which is the first CRISPR/Cas9-based treatment to win regulatory approval in the US.

The announcement is a landmark in the treatment of sickle cell disease, a devastating condition in which red blood cells deform into a sickle shape and clog up blood vessels. Sickle cell disease affects around 100,000 people in the US, most commonly African Americans. It leads to anemia, vaso-occlusive events and crises (painful episodes in which small blockages starve tissue of oxygen), strokes, progressive and irreversible organ damage, decreased quality of life, and early death.

Until today, treatments have been limited. A bone marrow transplant from a genetically matched sibling can cure the condition more than 90 percent of the time, but only around 20 percent of people with the disease have such a genetically matched sibling donor. There are also multiple drugs available and supportive care, but these mainly reduce the severity of the disease. The new gene therapy treatments, on the other hand, have shown to be highly effective at preventing vaso-occlusive events and crises.

“Sickle cell disease is a rare, debilitating and life-threatening blood disorder with significant unmet need, and we are excited to advance the field, especially for individuals whose lives have been severely disrupted by the disease, by approving two cell-based gene therapies today,” said Nicole Verdun, director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, said in the FDA’s announcement.

To understand how the gene therapies work, it’s useful to understand what causes sickle cell disease. The central problem is with adult hemoglobin, the iron-containing protein in red blood cells that transports oxygen from the lungs to the rest of the body. In patients with sickle cell disease, there’s a single, small mutation in the gene that encodes hemoglobin. The mutation is a switch of a single nucleotide, or base, (often represented by letters A, C, T, and G). The switch of an A to a T in the genetic code for hemoglobin results in a hemoglobin protein with a valine instead of a glutamic acid at the sixth amino acid position. This transforms normal adult hemoglobin (HbA) to sickle hemoglobin (HbS). In red blood cells, when HbS loses the oxygen it was carrying, it polymerizes with itself, forming strand-like structures that deform the cell.

Effective edits

The CRISPR/Cas9 therapy approved today, called Casgevy, prevents this deformation by essentially turning on the production of another type of hemoglobin encoded in our genetic blueprints—fetal hemoglobin (HbF). HbF is optimized for pregnancy, transferring oxygen from maternal blood to fetal tissue, and the gene that encodes it is shut off shortly after birth as the body transitions to HbA. About six months after birth, HbF usually makes up just 1 percent to 2 percent of hemoglobin in the body.

But, HbF can effectively treat sickle cell disease—the hemoglobin transports oxygen just fine in adults, and it doesn’t polymerize. Moreover, when it’s mixed with HbS, it gets in the way of the mutated protein polymerizing with itself, preventing it from forming structures that deform red blood cells.

Casgevy turns on HbF with the CRISPR/Cas9 system, a gene-editing system initially swiped from bacteria that snips DNA using an enzyme (a nuclease) called Cas9. Cas9 can be targeted to specific stretches of DNA using a short RNA guide sequence. In Casgevy, the CRISPR/Cas9 system is targeted to snip a gene encoding a protein called BCL11A, which controls other genes, aka a transcription factor. The BCL11A transcription factor is the protein responsible for shutting off the gene for HbF shortly after birth as the body transitions to the adult version. With the CRISPR/Cas9 snip, BCL11A is shut off, and HbF production can resume.

For patients being treated, this process involves first harvesting their bone marrow stem cells, which then get CRISPR-ed in a specialized lab. Meanwhile, the patients receive chemotherapy to kill bone marrow cells to make way for the gene-edited cells that are then put back in. Of 31 patients treated with Cagevy and followed for at least 24 months, 29 (93.5 percent) went at least 12 consecutive months without a vaso-occlusive crisis.

The other gene therapy approved by the FDA today is Lyfgenia, which used a Lentiviral vector to insert genes into the human genome. In this case, the system delivers the genetic code for a modified type of hemoglobin that is designed to be anti-sickling, called HbAT87Q. Among 32 patients treated with Lyfgenia, 28 (88 percent) were free of vaso-occlusive events for between six to 18 months after treatment.

Both gene therapies are approved for patients ages 12 years and up.

FDA approves first CRISPR therapy—here’s how it works against sickle cell Read More »

a-guided-demo-of-nanome-came-with-a-free-chemistry-lesson-from-founders

A Guided Demo of Nanome Came With a Free Chemistry Lesson From Founders

Before my life as a technology journalist, I worked in a university’s biomedical engineering research lab. Every now and then, in my current career, I encounter something that I wish had been around 10 years ago. Nanome, an app for spatially visualizing molecules in MR and VR, is exactly such an experience.

Meet Nanome

Nanome is a visualization and collaboration platform available on all major VR headsets. It’s partially funded by Meta, but founders got in with Oculus co-founder Michael Antonov long before Facebook bought the company (and subsequently changed the name of both companies to “Meta”).

“Because we were part of Oculus for Business as an ISV [Independent Software Vendor], our relationship has deepened and we have co-authored multiple case studies together, including for Nimbus and Novartis,” Nanome co-founder and CEO Steve McCloskey told ARPost.

Nanome VR app Set of plugins

Nanome was a launch title on the Quest Pro, but it is also available on Viveport and Steam. The platform runs in VR on most headsets, but also makes full use of the full-color passthrough on the Quest Pro. The company is looking at the emerging AR glasses hardware market, but still needs controllers for the time being.

“Current hand tracking technology does not meet the needs that 6DoF controllers can provide, which consumer AR glasses don’t,” said McCloskey. “Additionally, the limited FOV makes it challenging to get a closer view of molecules in the context of a protein binding pocket which is essential for many of our users.”

If you don’t know what a “protein binding pocket” is, don’t feel like Nanome is too advanced for you. Just like chemistry in general, you can start wherever you are and go from there. You can also watch educational videos on chemistry’s big ideas directly within Nanome.

“Every user has unique needs and workflows, and we aim to provide a tool that can adapt to those needs, rather than forcing users to adapt their workflows to our tool,” said McCloskey. “This is why we continually work to improve and expand our features, to provide an ever-more intuitive, collaborative, and integrative experience for our users.”

Subscription Options

Nanome comes in a free version for personal use, as well as academic, research, and enterprise subscription tiers. Virtually all of the platform’s major functionalities work in the free version, though the academic subscription allows meeting in private rooms and saving workspaces. The benefits of the remaining tiers come largely from hosting and server options.

Insights From the In-App Demo

I met with McCloskey and fellow co-founder Sam Hessenauer within a free trial of the platform’s academic version. Creating an account is fast and easy, and automatically uses your Meta avatar, though you can join with a number of default avatars if you’re using a borrowed or communal headset.

Start Building Molecules – Even Impossible Ones

The virtual space is initially empty, inviting users to start building their own molecules from scratch, using common building blocks already in the app, or bringing in completed structures. The app supports a number of commonly used visualization tools, so work started on conventional software can be brought directly into VR.

Nanome VR app - periodic table

Molecules have specific shapes – something about the constituent atoms attracting and repelling each other – I’m pretty sure that my university chemistry textbook has a whole section on figuring out bond angles based on valence electrons. The point is, the app does that for you. And, when you create a molecule that couldn’t possibly exist, the app lets you know.

So, if you want to play comic book super genius and create fantastic chemical structures, you can! And the app will let you know which parts of the molecule break the laws of physics, and which laws they break. You can also view the models in several color-coded visualization methods.

“Because we’re on the VR app store and the basic version of the software can replace Intro-to-Chem ball and stick models, we’re very popular among universities and libraries as the go-to chemistry app in XR,” said McCloskey. “You never run out of chemistry kit parts in XR!”

Building new chemical structures in the app is huge. While you certainly can use Nanome to practice and learn chemistry within its established boundaries, there are people using the platform to design new chemicals, like groundbreaking prescription medications. In fact, early feedback from Novartis went into the first widely available iteration of the platform.

“For other major biopharma companies, we meet scientists and IT folks at various industry conferences,” said McCloskey. “We have landed some deals from scientists who bought a Quest for the holidays and wanted to use Nanome at their workplace.”

Everyone Gather Around the Giant Protein

Visualizing chemicals isn’t only important when designing new ones. One giant model that McCloskey, Hessenauer, and I viewed within the space was a large protein. At that massive scale, something that was just an idea before suddenly seemed tangible and understandable –  a solid thing with its own charitable topography waiting to be explored.

Jon Nanome VR app demo

Prion proteins in the brain can fold incorrectly, leading to neurological disorders like dementia. I remember my middle school science teacher trying to communicate that by scribbling on the chalkboard, but how exactly a protein could be foldable never really made sense to me. Seeing that giant protein in VR, that fifteen-year-old lesson came back and clicked instantly.

McCloskey and Hessenauer were able to point out caves in the giant protein where part of another chemical – like a medication designed by one of the companies using the app – could fit into the protein and bind to it. I usually do demos like this to learn about XR, but this time I felt like I got a lesson in chemistry with XR in the margins – which is how it’s supposed to feel.

“As a design tool, we aim for Nanome to be as intuitive as possible. This is where XR and the user interface come into play,” said McCloskey. “We want our users to focus more on their scientific explorations and less on learning how to use the tool.”

Nanome VR app

Suppose I want to go back and watch our demo again. I can. But, not just a flat recording. Nanome allows spatial recordings that viewers can walk through later. If someone pointed at a point on the model and I missed it live, I can go back and watch it in VR standing right in their shoes as I relive the moment from their viewing angle.

At Least Take a Look

If you ever even think about chemistry, there’s literally no reason not to check out the free version of the app. If you’re a student, learning institution, or researcher, the platform can grow with you. The sheer number of things that Nanome can do are honestly overwhelming at first, but helpful explainer videos and easy-to-pick-up controls make it second nature in minutes.

A Guided Demo of Nanome Came With a Free Chemistry Lesson From Founders Read More »

swiss-scientists-figured-out-how-to-stop-your-glasses-from-fogging-up

Swiss scientists figured out how to stop your glasses from fogging up


Scientists at ETH Zurich have developed a special coating that prevents the lenses in glasses from fogging up. Apparently, not all heroes wear capes. This has been a problem since the advent of optical lenses, but it’s fair to say it reached a peak during the pandemic when everyone wearing glasses found out the hard way that most face masks vent your breath up towards your eyes. You’d think someone would have fixed this by now, but it’s harder than you might guess. The difficulty of the problem is evident by the lack of current solutions. You can wipe your glasses off when they fog up…

This story continues at The Next Web

Swiss scientists figured out how to stop your glasses from fogging up Read More »

european-mri-study-provides-experimental-evidence-indicating-our-brains-are-quantum

European MRI study provides experimental evidence indicating our brains are quantum


We’ve long suspected the human brain is a quantum computer but we’ve never had any actual evidence to back this theory up. That is, until now. A pair of researchers from Trinity College in Dublin and the Polish Academy of Sciences in Warsaw recently published what may turn out to be landmark research in the quest to understand the human brain, consciousness, and the physical nature of the universe itself. The team’s paper, titled “Experimental indications of non-classical brain functions,” details an experimental MRI paradigm in which it appeared test subjects’ brains were entangled with their hearts. Entanglement refers to…

This story continues at The Next Web

European MRI study provides experimental evidence indicating our brains are quantum Read More »